ERBB2 and breast carcinoma: The combination of trastuzumab (H), pertuzumab (P), and chemotherapy has become the standard of care for patients with HER2 overexpressing and/or amplified, that is, HER2‐positive, breast cancer (BC) in the neoadjuvant setting.